BridgeMD
New treatment option for Total Hip Arthroplasty (THA)
Official title Suzetrigine in Total Hip Arthroplasty
ClinicalTrials.gov ID: NCT07226700
What this study is testing
What is Suzetrigine?
Suzetrigine is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for total hip arthroplasty (tha).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80. Healthy volunteers may be eligible.
You may be able to join if
- Patients undergoing primary THA (posterior approach) with participating surgeons
- Age 18 to 80 years old
- Planned discharge to home
- Planned use of neuraxial anesthesia
- American Society of Anesthesiologists (ASA) Physical Status 1 - 3
You likely can't join if
- ASA greater than 3
- Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)
- History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)
- History of QT prolongation
- Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device
- Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse
See the full eligibility criteria
- Patients undergoing primary THA (posterior approach) with participating surgeons
- Age 18 to 80 years old
- Planned discharge to home
- Planned use of neuraxial anesthesia
- American Society of Anesthesiologists (ASA) Physical Status 1 - 3
- ASA greater than 3
- Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)
- History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)
- History of QT prolongation
- Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device
- Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse
- Inability to comply with any component of the study protocol
- Younger than 18 or greater than 80 years old at the time of enrollment
- Patient already on Suzetrigine
- Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease/Child Pugh B or C, use of strong CYP3 inhibitors or inducers)
- Contraindications to neuraxial anesthesia or any other part of the study protocol
- Participation in another investigational drug or device study
- Pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New York, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.